In vitro killing effect of moxifloxacin on clinical isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole

被引：20

作者：

Giamarellos-Bourboulis, EJ ^{[1
]}

Karnesis, L ^{[1
]}

Galani, I ^{[1
]}

Giamarellou, H ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Dept Internal Med 4, GR-11527 Athens, Greece

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2002年 / 46卷 / 12期

关键词：

D O I：

10.1128/AAC.46.12.3997-3999.2002

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The time-kill effect of moxifloxacin on 20 genetically distinct isolates of Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole was studied. The majority (80%) were killed by a concentration equivalent to four times the MIC; the MIC induced a transient decrease in bacterial counts at 4 h, followed by regrowth. No effect was detected in four isolates. These results merit further clinical consideration.

引用

页码：3997 / 3999

页数：3

共 12 条

[1] Genotypic and phenotypic relationships between clinical and environmental isolates of Stenotrophomas maltophilia [J].

Berg, G ;

Roskot, N ;

Smalla, K .

JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (11) :3594-3600

[2] Antibiotic resistance surveillance of Stenotrophomonas maltophilia, 1993-1999 -: J Antimicrob Chemother 2001;: 48:152-154 [J].

Betriu, C ;

Sánchez, A ;

Palau, ML ;

Gómez, M ;

Picazo, JJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (01) :152-154

[3] Comparative in vitro activity of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia species isolates including evaluation of disk diffusion and E test methods [J].

Biedenbach, DJ ;

Croco, MAT ;

Barrett, TJ ;

Jones, RN .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (06) :428-431

[4] Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients:: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999) [J].

Gales, AC ;

Jones, RN ;

Forward, KR ;

Liñares, J ;

Sader, HS ;

Verhoef, J .

CLINICAL INFECTIOUS DISEASES, 2001, 32 :S104-S113

[5]

Hindler, 1992, CLIN MICROBIOLOGY PR

[6] Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy [J].

Soman, A ;

Honeybourne, D ;

Andrews, J ;

Jevons, G ;

Wise, R .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (06) :835-838

[7] Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man [J].

Stass, H ;

Kubitza, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 :83-90

[8]

Tsiodras S, 2000, SCAND J INFECT DIS, V32, P651, DOI 10.1080/003655400459577

[9] Antimicrobial susceptibilities of unique Stenotrophomonas maltophilia clinical strains [J].

Valdezate, S ;

Vindel, A ;

Loza, E ;

Baquero, F ;

Cantón, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (05) :1581-1584

[10] Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia [J].

Weiss, K ;

Restieri, C ;

De Carolis, E ;

Laverdière, M ;

Guay, H .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (03) :363-365

← 1 2 →